A triple-blinded randomized control trial to evaluate the safety and immunogenicity of fractional doses of COVID-19 vaccines (ChAd0x1, AD26.COV2. S, and BNT162B2) among Nigeria adults: the SIFCoVAN trial
一项三盲随机对照试验，旨在评估尼日利亚成年人接种不同剂量新冠病毒疫苗（ChAd0x1、AD26.COV2.S 和 BNT162B2）的安全性和免疫原性：SIFCoVAN 试验
期刊:Trials
影响因子:2
doi:10.1186/s13063-025-09317-4
Musa, Adesola Zaidat; Salako, Abideen Olurotimi; Ayorinde, James Babatunde; Ekama, Sabdat; Odubela, Oluwatosin Olaseni; Ige, Fehintola; Idigbe, Ifeoma Eugenia; Ajibaye, Olusola; Odubela, Olayemi Rafiah; Egharevba, Henry; Ekpenyong, Magaret; Adeneye, Kazeem; Folahanmi, Akinsolu Tomiwa; Olojo, Ifedola Isimeme; Fowora, Muinah Adenike; Okwuraiwe, Azuka; Elemuwa, Uchenna; Ezenyi, Ifeoma; Fraden, Bitrus; Oba, Abdulrasheed; Idris, Ganiu Adigun; Jimoh, Yusuf; Akande, Ibukun Ruth; Ogunwale, Joy; Nwaiwu, Stephine Ogechi; Omale, Ojoma Louisa; Oyewunmi, Oluwatobiloba Oyewunmi; Ezeanowi, Rufina; Agbabiaka, Adedoyin; Eyinade, Olajumoke; Osho, Abdulhakeem; Garba, Abdullah; Yahya, Bello; Musa, Baba Maiyaki; Ezejiofor, Ogochukwu; Ejiro, Ben; Iwalokun, Bamidele Abiodun; Adigwe, Obi Peter; Adeyeye, Mojisola Christianah; Faisal, Shuaib; Ezechi, Oliver Chukwujekwu; Salako, Babatunde Lawal
